Skip to main content
Erschienen in: Heart and Vessels 9/2022

12.03.2022 | Original Article

Prediction of type 4a myocardial infarction with the angiography-derived hemodynamic (ADDED) index

verfasst von: Fabio Mangiacapra, Raffaele Rinaldi, Iginio Colaiori, Alessandro Sticchi, Michele Mattia Viscusi, Luca Paolucci, Massimo Russo, Annunziata Nusca, Rosetta Melfi, Elisabetta Ricottini, Paolo Gallo, Gian Paolo Ussia, Francesco Grigioni

Erschienen in: Heart and Vessels | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Abstract

Percutaneous coronary intervention (PCI) is frequently complicated by type 4a myocardial infarction (MI), which is associated with an increased risk of mortality. We assessed the usefulness of the angiography-derived hemodynamic index (ADDED), which is based on the extent of myocardium at risk and on the anatomical lesion severity, in predicting type 4a MI in patients with chronic coronary syndrome (CCS) undergoing PCI. We enrolled 442 patients treated with single-vessel PCI. The ADDED index was calculated as the ratio of the Duke Jeopardy Score to the minimum lumen diameter assessed with quantitative angiography analysis. Type 4a MI was defined according to the 4th Universal Definition of MI. The overall population was divided into tertiles of ADDED index. Type 4a MI occurred in 5 patients (3.3%) in the ADDED-low tertile, 8 (5.5%) in the ADDED-mid tertile, and 26 (17.7%) in the ADDED-high tertile (p < 0.0001). At ROC curve analysis, the ADDED index could significantly discriminate between patients with and without type 4a MI (area under the curve 0.745). At multivariate analysis, an ADDED index value > 5.25 was the strongest independent predictor type 4a MI. Our results support the role of the ADDED index as a predictor of type 4a MI in patients with CCS treated with elective PCI of a single vessel. Whether a selective use of additional preventive measures in patients considered at high risk based on ADDED index values may improve peri-procedural and long-term outcomes remains to be tested in dedicated investigations.
Literatur
1.
Zurück zum Zitat Timmis A, Townsend N, Gale C, Grobbee R, Maniadakis N, Flather M, Wilkins E, Wright L, Vos R, Bax J, Blum M, Pinto F, Vardas P, ESC Scientific Document Group (2018) European society of cardiology: cardiovascular disease statistics 2017. Eur Heart J 39:508–579CrossRef Timmis A, Townsend N, Gale C, Grobbee R, Maniadakis N, Flather M, Wilkins E, Wright L, Vos R, Bax J, Blum M, Pinto F, Vardas P, ESC Scientific Document Group (2018) European society of cardiology: cardiovascular disease statistics 2017. Eur Heart J 39:508–579CrossRef
2.
Zurück zum Zitat Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/ American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction (2018) Fourth universal definition of myocardial infarction. J Am Coll Cardiol 72:2231–2264CrossRef Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/ American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction (2018) Fourth universal definition of myocardial infarction. J Am Coll Cardiol 72:2231–2264CrossRef
3.
Zurück zum Zitat Hara H, Serruys PW, Takahashi K, Kawashima H, Ono M, Gao C, Wang R, Mohr FW, Holmes DR, Davierwala PM, Head SJ, Thuijs DJFM, Milojevic M, Kappetein AP, Garg S, Onuma Y, Mack MJ, Extended Survival Investigators SYNTAX (2020) Impact of peri-procedural myocardial infarction on outcomes after revascularization. J Am Coll Cardiol 76:1622–1639CrossRef Hara H, Serruys PW, Takahashi K, Kawashima H, Ono M, Gao C, Wang R, Mohr FW, Holmes DR, Davierwala PM, Head SJ, Thuijs DJFM, Milojevic M, Kappetein AP, Garg S, Onuma Y, Mack MJ, Extended Survival Investigators SYNTAX (2020) Impact of peri-procedural myocardial infarction on outcomes after revascularization. J Am Coll Cardiol 76:1622–1639CrossRef
4.
Zurück zum Zitat Silvain J, Zeitouni M, Paradies V, Zheng HL, Ndrepepa G, Cavallini C, Feldman DN, Sharma SK, Mehilli J, Gili S, Barbato E, Tarantini G, Ooi SY, von Birgelen C, Jaffe AS, Thygesen K, Montalescot G, Bulluck H, Hausenloy DJ (2021) Cardiac procedural myocardial injury, infarction, and mortality in patients undergoing elective percutaneous coronary intervention: a pooled analysis of patient-level data. Eur Heart J 42:323–334CrossRef Silvain J, Zeitouni M, Paradies V, Zheng HL, Ndrepepa G, Cavallini C, Feldman DN, Sharma SK, Mehilli J, Gili S, Barbato E, Tarantini G, Ooi SY, von Birgelen C, Jaffe AS, Thygesen K, Montalescot G, Bulluck H, Hausenloy DJ (2021) Cardiac procedural myocardial injury, infarction, and mortality in patients undergoing elective percutaneous coronary intervention: a pooled analysis of patient-level data. Eur Heart J 42:323–334CrossRef
5.
Zurück zum Zitat Tricoci P, Newby LK, Clare RM, Leonardi S, Gibson CM, Giugliano RP, Armstrong PW, Van de Werf F, Montalescot G, Moliterno DJ, Held C, Aylward PE, Wallentin L, Harrington RA, Braunwald E, Mahaffey KW, White HD (2018) Prognostic and practical validation of current definitions of myocardial infarction associated with percutaneous coronary intervention. JACC Cardiovasc Interv 11:856–864CrossRef Tricoci P, Newby LK, Clare RM, Leonardi S, Gibson CM, Giugliano RP, Armstrong PW, Van de Werf F, Montalescot G, Moliterno DJ, Held C, Aylward PE, Wallentin L, Harrington RA, Braunwald E, Mahaffey KW, White HD (2018) Prognostic and practical validation of current definitions of myocardial infarction associated with percutaneous coronary intervention. JACC Cardiovasc Interv 11:856–864CrossRef
6.
Zurück zum Zitat Zeitouni M, Silvain J, Guedeney P, Kerneis M, Yan Y, Overtchouk P, Barthelemy O, Hauguel-Moreau M, Choussat R, Helft G, Le Feuvre C, Collet JP, Montalescot G, ACTION Study Group (2018) Periprocedural myocardial infarction and injury in elective coronary stenting. Eur Heart J 39:1100–1109CrossRef Zeitouni M, Silvain J, Guedeney P, Kerneis M, Yan Y, Overtchouk P, Barthelemy O, Hauguel-Moreau M, Choussat R, Helft G, Le Feuvre C, Collet JP, Montalescot G, ACTION Study Group (2018) Periprocedural myocardial infarction and injury in elective coronary stenting. Eur Heart J 39:1100–1109CrossRef
7.
Zurück zum Zitat Di Serafino L, Scognamiglio G, Turturo M, Esposito G, Savastano R, Lanzone S, Trimarco B, D’Agostino C (2016) FFR prediction model based on conventional quantitative coronary angiography and the amount of myocardium subtended by an intermediate coronary artery stenosis. Int J Cardiol 223:340–344CrossRef Di Serafino L, Scognamiglio G, Turturo M, Esposito G, Savastano R, Lanzone S, Trimarco B, D’Agostino C (2016) FFR prediction model based on conventional quantitative coronary angiography and the amount of myocardium subtended by an intermediate coronary artery stenosis. Int J Cardiol 223:340–344CrossRef
9.
Zurück zum Zitat Califf RM, Phillips HR, Hindman MC, Mark DB, Lee KL, Behar VS, Johnson RA, Pryor DB, Rosati RA, Wagner GS (1985) Prognostic value of a coronary artery jeopardy score. J Am Coll Cardiol 5:1055–1063CrossRef Califf RM, Phillips HR, Hindman MC, Mark DB, Lee KL, Behar VS, Johnson RA, Pryor DB, Rosati RA, Wagner GS (1985) Prognostic value of a coronary artery jeopardy score. J Am Coll Cardiol 5:1055–1063CrossRef
10.
Zurück zum Zitat Mangiacapra F, Cavallari I, Ricottini E, Pellicano M, Barbato E, Di Sciascio G (2015) High platelet reactivity and periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention: A significant association beyond definitions. Int J Cardiol 190:124–125CrossRef Mangiacapra F, Cavallari I, Ricottini E, Pellicano M, Barbato E, Di Sciascio G (2015) High platelet reactivity and periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention: A significant association beyond definitions. Int J Cardiol 190:124–125CrossRef
11.
Zurück zum Zitat Soud M, Ho G, Kuku KO, Hideo-Kajita A, Waksman R, Garcia-Garcia HM (2018) Impact of statins preloading before PCI on periprocedural myocardial infarction among stable angina pectoris patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. Cardiovasc Revasc Med 19:971–975CrossRef Soud M, Ho G, Kuku KO, Hideo-Kajita A, Waksman R, Garcia-Garcia HM (2018) Impact of statins preloading before PCI on periprocedural myocardial infarction among stable angina pectoris patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. Cardiovasc Revasc Med 19:971–975CrossRef
12.
Zurück zum Zitat Mangiacapra F, Peace AJ, Di Serafino L, Pyxaras SA, Bartunek J, Wyffels E, Heyndrickx GR, Wijns W, De Bruyne B, Barbato E (2013) Intracoronary enalaprilat to reduce MICROvascular damage during percutaneous coronary intervention (ProMicro) study. J Am Coll Cardiol 61:615–621CrossRef Mangiacapra F, Peace AJ, Di Serafino L, Pyxaras SA, Bartunek J, Wyffels E, Heyndrickx GR, Wijns W, De Bruyne B, Barbato E (2013) Intracoronary enalaprilat to reduce MICROvascular damage during percutaneous coronary intervention (ProMicro) study. J Am Coll Cardiol 61:615–621CrossRef
13.
Zurück zum Zitat Mangiacapra F, Di Gioia G, Pellicano M, Di Serafino L, Bressi E, Peace AJ, Bartunek J, Wijns W, De Bruyne B, Barbato E (2016) Effects of prasugrel versus clopidogrel on coronary microvascular function in patients undergoing elective PCI. J Am Coll Cardiol 68:235–237CrossRef Mangiacapra F, Di Gioia G, Pellicano M, Di Serafino L, Bressi E, Peace AJ, Bartunek J, Wijns W, De Bruyne B, Barbato E (2016) Effects of prasugrel versus clopidogrel on coronary microvascular function in patients undergoing elective PCI. J Am Coll Cardiol 68:235–237CrossRef
14.
Zurück zum Zitat Mehilli J, Baquet M, Hochholzer W, Mayer K, Tesche C, Aradi D, Xu Y, Thienel M, Gschwendtner S, Zadrozny M, Jochheim D, Sibbing D, Schüpke S, Mansmann U, Hoffmann E, Kastrati A, Neumann FJ, Massberg S (2020) Randomized comparison of intensified and standard P2Y12-receptor-inhibition before elective percutaneous coronary intervention: the SASSICAIA trial. Circ Cardiovasc Interv 13:8649CrossRef Mehilli J, Baquet M, Hochholzer W, Mayer K, Tesche C, Aradi D, Xu Y, Thienel M, Gschwendtner S, Zadrozny M, Jochheim D, Sibbing D, Schüpke S, Mansmann U, Hoffmann E, Kastrati A, Neumann FJ, Massberg S (2020) Randomized comparison of intensified and standard P2Y12-receptor-inhibition before elective percutaneous coronary intervention: the SASSICAIA trial. Circ Cardiovasc Interv 13:8649CrossRef
15.
Zurück zum Zitat Silvain J, Lattuca B, Beygui F, Rangé G, Motovska Z, Dillinger JG, Boueri Z, Brunel P, Lhermusier T, Pouillot C, Larrieu-Ardilouze E, Boccara F, Labeque JN, Guedeney P, El Kasty M, Laredo M, Dumaine R, Ducrocq G, Collet JP, Cayla G, Blanchart K, Kala P, Vicaut E, Montalescot G, Investigators ALPHEUS (2020) Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial. Lancet 396:1737–1744CrossRef Silvain J, Lattuca B, Beygui F, Rangé G, Motovska Z, Dillinger JG, Boueri Z, Brunel P, Lhermusier T, Pouillot C, Larrieu-Ardilouze E, Boccara F, Labeque JN, Guedeney P, El Kasty M, Laredo M, Dumaine R, Ducrocq G, Collet JP, Cayla G, Blanchart K, Kala P, Vicaut E, Montalescot G, Investigators ALPHEUS (2020) Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial. Lancet 396:1737–1744CrossRef
16.
Zurück zum Zitat Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, Leonardi S, Liu T, Skerjanec S, Day JR, Iwaoka RS, Stuckey TD, Gogia HS, Gruberg L, French WJ, White HD, Harrington RA, Investigators CHAMPION (2013) Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 382:1981–1992CrossRef Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, Leonardi S, Liu T, Skerjanec S, Day JR, Iwaoka RS, Stuckey TD, Gogia HS, Gruberg L, French WJ, White HD, Harrington RA, Investigators CHAMPION (2013) Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 382:1981–1992CrossRef
17.
Zurück zum Zitat Mangiacapra F, Pellicano M, Di Serafino L, Bressi E, Peace AJ, Di Gioia G, Morisco C, Bartunek J, Wijns W, Bruyne B, Barbato E (2018) Platelet reactivity and coronary microvascular impairment after percutaneous revascularization in stable patients receiving clopidogrel or prasugrel. Atherosclerosis 278:23–28CrossRef Mangiacapra F, Pellicano M, Di Serafino L, Bressi E, Peace AJ, Di Gioia G, Morisco C, Bartunek J, Wijns W, Bruyne B, Barbato E (2018) Platelet reactivity and coronary microvascular impairment after percutaneous revascularization in stable patients receiving clopidogrel or prasugrel. Atherosclerosis 278:23–28CrossRef
Metadaten
Titel
Prediction of type 4a myocardial infarction with the angiography-derived hemodynamic (ADDED) index
verfasst von
Fabio Mangiacapra
Raffaele Rinaldi
Iginio Colaiori
Alessandro Sticchi
Michele Mattia Viscusi
Luca Paolucci
Massimo Russo
Annunziata Nusca
Rosetta Melfi
Elisabetta Ricottini
Paolo Gallo
Gian Paolo Ussia
Francesco Grigioni
Publikationsdatum
12.03.2022
Verlag
Springer Japan
Erschienen in
Heart and Vessels / Ausgabe 9/2022
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-022-02050-x

Weitere Artikel der Ausgabe 9/2022

Heart and Vessels 9/2022 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.